Please login to the form below

NPS

This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.

The lead NASH candidate at that time was NP 201, but seems to have been leapfrogged by NGM313, now renamed MK-3655.

Redmile and Google help Evox raise £35.5m for exosome pipeline

Two proteins (NP-C1 and NP-C2) help control lipid transport within cells in patients with this disorder, with the majority (95%) of cases involving mutations in the NP-C1 gene.
Shire finally bags EU approval for rare disease drug Natpar

Natpar was one of the primary reasons Shire forked out $5.2bn to buy NPS Pharma in 2015 just before the FDA gave its go-ahead for the new therapy, which
Sweet emotion

1100%; improving NPS scores.
Finalists revealed for Communiqué Awards 2016

Think Again. Think NP-C - an international campaign to increase NP-C recognition among clinicians and reduce time to diagnosis.
Shire deal with Baxalta predicted this week

HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Biotech profile: Tom Evans, CEO, Vaccitech.

As many of the safety and manufacturing issues surrounding our MVA-NP M1 vaccine are already de-risked, a positive efficacy readout in the challenge study should allow us to take
Digital mania - a question of value

So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).
A rare talent

$6bn deal that was completed in January 2016. Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and
Deal Watch table for January 2015

NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.
Pharma deals during January 2015

Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Prevail Therapeutics adds to its board of directors

From 2008-2015 Nader was president and chief executive officer of NPS Pharma, until Shire acquired the company for $5.2bn. ... Before his time at NPS, Nader was a venture partner at Care Capital and he also previously served on the North America
CRISPR Therapeutics appoints Dr Tony Coles

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.
Patrick Fabbio named CFO at electroCore

He joins from NPS Pharmaceuticals where he was VP finance. US-based electroceutical healthcare company electroCore has named Patrick Fabbio as chief financial officer. ... Fabbio has over 20 years of financial leadership experience in public and private

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...